

1    **The future of antivirals: broad-spectrum inhibitors**

2    Yannick Debing, Johan Neyts, Leen Delang<sup>#</sup>

3

4    Rega Institute for Medical Research, KU Leuven

5

6    <sup>#</sup>Corresponding author: Dr. Leen Delang, Minderbroedersstraat 10, 3000 Leuven, Belgium.

7    [Leen.Delang@rega.kuleuven.be](mailto:Leen.Delang@rega.kuleuven.be), tel +3216337343, fax +3216337340.

## **Abstract**

**Purpose of review.** Potent antivirals are successfully used for the treatment of infections with herpesviruses, hepatitis B and C virus and HIV and with some success for influenza viruses. However, no selective inhibitors are available for a multitude of medically important viruses, most of which are (re-)emerging RNA viruses. Since it is impossible to develop drugs against each of these viruses, broad-spectrum antiviral agents (BSAA) are a prime strategy to cope with this challenge.

**Recent findings.** We propose four categories of antiviral molecules that hold promise as BSAA. Several nucleoside analogues with broad antiviral activity have been described and given the relatively conserved nature of viral polymerases, it may be possible to develop more broad-spectrum nucleoside analogues. A number of viral proteins are relatively conserved between families and may also be interesting targets. Host-targeting antiviral drugs such as modulators of lipid metabolism and cyclophilin inhibitors can be explored as well. Finally, the potent and broad antiviral function of the immune system can be cooperated to develop immune-modulating BSAA.

**Summary.** Despite the recent advances, the BSAA-field is still in its infancy. Nevertheless, the discovery and development of such molecules will be a key aim of antiviral research in the coming decades.

**Keywords:** antiviral therapy; broad-spectrum antiviral agents; nucleoside analogues; host-targeting antivirals; immune modulation.

## **Introduction**

Several epidemics of (re-)emerging viruses startled the world during the last decennia. The recent Ebola virus outbreak in West-Africa and the MERS epidemic in the Middle East and South Korea made clear that antivirals are urgently needed against a number of viruses and viral families for which no such drugs are available. Indeed, potent antivirals (or combinations thereof) are only available to treat infections with a limited number of viruses, i.e. herpesviruses, hepatitis B and C virus (HBV, HCV), HIV and to some extent for influenza virus. For many other viruses, including neglected and/or emerging RNA viruses that are sometimes highly pathogenic, like the ebolavirus, there are no antiviral treatment options. Furthermore, it can be expected that new, potentially pathogenic viruses will emerge in the future. Because it will not be economically viable to develop specific drugs for each individual virus, the development of broad-spectrum antiviral agents (BSAA) is believed to be essential to address the challenge of viral infections, both common and (re-)emerging. A first major and probably feasible achievement would be the development of molecules with broad antiviral activity within one virus family (pan-picornavirus, pan-alphavirus etc.). However, the 'holy grail' would ultimately be the discovery of antiviral molecules that target more than one virus family, or even all RNA viruses or all enveloped viruses. The development of BSAA may be focused on targeting a viral protein, but could also modulate a host cell factor. In this review, we will discuss possible strategies to develop broad-spectrum antiviral agents and highlight promising candidates and strategies.

## **Direct-acting broad-spectrum antiviral agents**

### ***Nucleoside and nucleotide analogues***

Modified nucleosides and nucleotides have been among the earliest marketed antiviral drugs [1]. They are the cornerstone of anti-HIV therapy (e.g. tenofovir, emtricitabine, lamivudine,...) and crucial for the treatment of herpesvirus infections (aciclovir, ganciclovir, cidofovir,...) [1]. Some nucleoside analogues exert antiviral activity against an elaborate spectrum of viruses. Ribavirin is probably the

1 most well-known antiviral nucleoside with a broad antiviral activity and is used to treat chronic  
2 hepatitis C and E, respiratory syncytial virus (RSV) infections and with some success for the treatment  
3 of Lassa fever and hantavirus infection [2–6]. Secondly, several 2'-C-methylated nucleosides that had  
4 been discovered as HCV inhibitors were found to exert antiviral activity against several positive-sense  
5 RNA viruses. Sofosbuvir (a prodrug form of 2'-deoxy-2'- $\alpha$ -fluoro- $\beta$ -C-methyluridine) is now  
6 successfully being used for the treatment of HCV infections but has less pronounced or no activity  
7 against other RNA viruses [7,8]. By contrast, the prototype inhibitor 2'-C-methylcytidine inhibits a  
8 rather broad-spectrum of positive-sense RNA viruses including flavi-, noro- and picornaviruses [9–  
9 11]. Moreover, favipiravir, also known as T-705, has antiviral activity against both positive- and  
10 negative-sense RNA viruses [12]. This molecule is regarded as a nucleobase and is intracellularly  
11 metabolized to a nucleotide analogue that inhibits the influenza RNA-dependent RNA polymerase.  
12 The compound has been approved in Japan for the treatment of influenza virus infections. Similarly,  
13 the adenosine analogue BCX4430 acts as a chain terminator of RNA virus polymerases and elicits *in*  
14 *vitro* antiviral activity against most positive- and negative-sense RNA viruses. BCX4430 is most potent  
15 against filoviruses and protective activity has been demonstrated in filovirus-infected primates [13].  
16 Nevertheless, these drugs exhibit either toxicity and strong side effects (e.g. 2'-C-methylcytidine,  
17 ribavirin), limited clinical efficacy against some viruses (e.g. ribavirin against RSV infections) and/or  
18 they are still in (early) development [14–16]. Finally, the spectrum of susceptible viral species is often  
19 too limited for these drugs to be considered true BSAA.

20 Despite the drawbacks and limitations of the currently available nucleoside analogues, this class of  
21 molecules still holds great promise to deliver *bona fide* BSAA. The replication of the viral genome is  
22 an essential part of the viral life cycle and consequently most viruses encode their own polymerases  
23 which are significantly divergent from their mammalian counterparts. There is a certain degree of  
24 conservation within each type of polymerase family (e.g. DNA- or RNA-dependent,... [17]), suggesting  
25 the possibility to develop BSAA that inhibit virtually all polymerases of a certain type. To identify lead  
26 molecules for further development into such nucleoside-based BSAA, a tailored screening approach

may be quintessential. An enormous collection of nucleoside and nucleotide analogues has been synthesized to date [18]; a first step in a successful screening campaign would therefore be the rigorous selection of a high-end nucleoside library based on criteria such as structural diversity, drug-like characteristics, cell-permeability, solubility, etc. This library can subsequently be tested using a specifically designed screening procedure. A first possibility for such screening would be to use high-throughput enzymatic polymerase assays [19,20] where all selected molecules are tested against several representative viral polymerases of a certain type (e.g. RNA-dependent RNA polymerases from different virus families), searching for molecules that inhibit all tested enzymes. Another approach might be to evaluate such libraries in phenotypic cell-based antiviral assays against a panel of viruses that are representative for particular genera, families or groups of viruses. A third strategy is the rational design of nucleotide analogues based on a comparison of available polymerase crystal structures and specifically the conserved features in the catalytic site. Further development of hit molecules would include expanding the number of tested viruses and chemical modification of the initial hit (so-called hit explosion) to increase antiviral potency and the number of susceptible agents, but also to improve selectivity and pharmacokinetic parameters. Since some of the DNA virus-targeting nucleoside analogues already have a rather broad-spectrum of activity, these efforts should probably be directed towards RNA viruses initially.

### ***Viral protease inhibitors***

Besides the viral polymerase, the viral protease is one of the most studied antiviral targets and virus-specific protease inhibitors are used successfully to treat HIV and HCV infections. The development of protease inhibitors targeting multiple virus families might be an interesting strategy. Based on phylogenetic analysis, picornaviruses, caliciviruses and coronaviruses can be classified in the picornavirus-like supercluster [21]. These viruses all have 3C or 3C-like proteases with a typical chymotrypsin-like fold and a catalytic triad (or dyad) containing a cysteine residue as a nucleophile, making them interesting targets for BSAA development. Rupintrivir for instance is an irreversible 3C-

protease inhibitor that was originally developed for the treatment of human rhinovirus infections [22] and antiviral activity has also been shown against other picornaviruses, coronaviruses and norovirus [23–25]. Other inhibitors of 3C-like proteases were reported with broad-spectrum antiviral activity against both feline coronaviruses and caliciviruses [26]. Therefore, the design of BSAA targeting proteases of different virus families appears feasible and could be a good strategy to develop broader-spectrum antivirals.

### **Host-targeting antivirals (HTA) as BSAA**

Targeting a host protein that is essential in the viral life cycle of different virus families could be a second attractive strategy for broad-spectrum antiviral intervention. However, this strategy is still somewhat controversial since inhibiting the primary roles of host factors may result in toxicity or adverse effects and polymorphisms in a host factor and variable expression levels between patients might be problematic. On the other hand, the selection of viral resistance, which is a major problem for conventional virus-specific drugs, is probably lower for a HTA. The feasibility of HTA strategies will likely depend on which host factor is targeted and how the viruses and the cell depend on its function(s). Modulators of the host lipid metabolism, nitazoxanide and cyclophilin inhibitors are host-targeting antivirals that are considered as potential BSAA.

### ***Modulators of lipid metabolism***

Many viruses are highly dependent on the host lipid metabolism for replication [27]. The lipid metabolism is therefore considered a prime target for BSAA. One of the most widely used classes of lipid modulators are the cholesterol-lowering statins. Statins inhibit the 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, the rate-limiting enzyme involved in cholesterol biosynthesis in the liver. Statins have been reported to possess *in vitro* antiviral activity against a variety of viruses, such as HCV, HIV, poliovirus, cytomegalovirus, dengue virus and RSV [28–35]. Nevertheless, studies evaluating the antiviral efficacy of statins in patients yielded contradictory results. In HCV-infected

1 patients for instance, a modest or even no antiviral effect of statins was observed when used as a  
2 monotherapy. However, in combination with the previous standard of care (pegylated interferon- $\alpha$   
3 and ribavirin) a significant increase in sustained virological response rates was observed [36,37]. The  
4 potential use of statins as BSAA will require more study to prove its *in vivo* antiviral efficacy.

5 Arbidol is another lipid modulator that is approved in China and Russia for the prophylaxis and  
6 treatment of influenza and other respiratory viral infections. This indole derivative also inhibits the  
7 replication of many other enveloped and non-enveloped RNA and DNA viruses, including HBV, HCV  
8 and chikungunya virus [38]. Recent studies suggest that arbidol has a dual mechanism of action: it  
9 binds to lipid membranes and interacts with aromatic amino acids in the viral envelope glycoprotein  
10 [39]. In this way, it interferes with viral entry and membrane fusion. Arbidol combines good  
11 bioavailability with a safe record of use in patients, making it a promising BSAA candidate [40];  
12 however, *in vivo* studies confirming its antiviral effect are only sparsely available.

13 Finally, LJ001 is a lipophilic thiazolidine derivative that is effective against several enveloped viruses  
14 including influenza virus, HIV and filoviruses [41]. In contrast, the compound has no effect on non-  
15 enveloped viruses. LJ001 targets the viral lipid envelope and hampers its ability to mediate virion-cell  
16 fusion. Recent studies showed that LJ001 induced lipid oxidation, thereby negatively impacting the  
17 biophysical properties of membranes (such as curvature and fluidity) needed for viral fusion [41].  
18 Unfortunately, LJ001 itself is unsuitable for further development because of its poor physiological  
19 stability and the requirement of light for its antiviral mechanism. New analogues have been  
20 developed to overcome these negative characteristics [42]. These analogues have improved antiviral  
21 activity, better pharmacokinetic characteristics and altered light-absorbing properties. However,  
22 when evaluated in a mouse infection model of Rift Valley fever virus, these molecules were only able  
23 to delay the time of death [42]. Although this particular class of molecules seems less suitable for  
24 clinical development, the viral membrane could still be a viable target for BSAAAs that disturb viral-cell  
25 fusion [43,44]. Squalamine is another compound that targets the host membrane, but its mechanism  
26 of action differs from LJ001 and analogues. Squalamine is a compound isolated from the dogfish

shark and the sea lamprey that inhibits enveloped RNA and DNA viruses both *in vitro* and *in vivo* [45]. The mechanism of antiviral activity is proposed to be the neutralization of the negative electrostatic surface charge of intracellular membranes, thereby making the cellular environment less favorable for viral replication. This disruption of electrostatic potential does not result in structural damage of cellular membranes, as measured by changes in cell permeability [46]. As squalamine can be readily synthesized [47] and has already been studied in humans in several phase 2 clinical trials for cancer and retinal vasculopathies without serious adverse events [48], its potential to be used as a BSAA could be further explored.

### **Nitazoxanide**

Nitazoxanide was originally developed and commercialized as an antiprotozoal agent and was licensed in the USA as an orphan drug for the treatment of diarrhea caused by *Cryptosporidium parvum* and *Giardia intestinalis* [49]. It is also widely used in India and Latin-America to treat intestinal parasitic infections. In addition to its anti-parasitic activity, nitazoxanide inhibits a broad range of unrelated RNA and DNA viruses [50]. Nitazoxanide inhibits the influenza virus by blocking the maturation of the viral hemagglutinin at the post-translational stage [51]. In HCV-infected cell cultures, nitazoxanide activated protein kinase R, an important component of the innate immune system [52]. The antiviral efficacy of nitazoxanide has also been evaluated in patients. A phase 2b/3 clinical study in patients with laboratory-confirmed influenza showed that nitazoxanide decreased the duration of clinical symptoms and reduced viral shedding compared to placebo [53]. A large phase 3 trial is ongoing. Phase 2 studies also demonstrated that nitazoxanide significantly reduced the duration of symptoms in patients infected with rotavirus or norovirus [54]. For HCV-infected patients, clinical studies showed improved responses when nitazoxanide was combined with pegylated interferon [55]; however, the clinical development for HCV treatment was discontinued due to the recent approval of direct-acting antivirals. The broad-spectrum antiviral activity together with the high barrier for resistance and proven *in vivo* efficacy for some viral infections make



1 nitazoxanide an attractive candidate to be developed as a BSAA. Initially, clinical development of this  
2 drug will primarily focus on viral respiratory infections and gastroenteritis.

#### 4 ***Cyclophilin antagonists***

5 The cyclophilins are peptidyl-prolyl cis/trans-isomerases that are required for the proper folding of  
6 certain host proteins [56] and also to play an important role in the life cycles of diverse viruses [57].  
7 Cyclosporine A and sanglifehrin A are immunosuppressive molecules that inhibit cyclophilins [58]. By  
8 chemical modification, analogues were generated without immunosuppressive properties. These  
9 cyclophilin inhibitors inhibit a broad range of RNA and DNA viruses, both *in vitro* and in animal  
10 models [57]. The most advanced molecules are alisporivir and SCY-635. These molecules  
11 demonstrated therapeutic efficacy in HCV-infected patients [59,60]. Mechanistically, cyclophilin A  
12 (CypA) was shown to interact with the HCV NS5A protein [61,62] and multiple mutations in NS5A  
13 were required to confer *in vitro* resistance to alisporivir, suggesting a high barrier to resistance  
14 [62,63]. For HIV, it was reported that CypA binds to the capsid protein p24 [64]. Although cyclophilin  
15 inhibitors potently suppress HIV infection *in vitro* and in the majority of patients, naturally pre-  
16 existing capsid variants resistant to treatment were observed and preclude the broad therapeutic use  
17 of cyclophilin inhibitors against HIV [65,66]. However, as cyclophilins are indispensable for the  
18 replication of many viruses, these proteins may be an interesting host target for the development of  
19 BSAA. Furthermore, CypA knockout studies in a human cell line and in mice showed that CypA is not  
20 essential for basic cell survival [67,68], countering concerns for associated cellular toxicity. However,  
21 the *in vivo* efficacy of cyclophilin inhibitors will need to be demonstrated for other viruses.

#### 23 **Immune modulation**

24 Lastly, the immune system can be regarded as the most broad-spectrum antiviral mechanism  
25 currently known. By combining innate and adaptive immune mechanisms, most microbial infections  
26 can be cleared successfully. However, in particular cases, the immune system is unable to eliminate

1 the pathogen (e.g. chronic viral hepatitis, herpesvirus latency, HIV infections,...) or its actions may be  
2 damaging the host (for instance during RSV infection [69]). Many viruses circumvent or even  
3 cooperate the immune response for their own benefit [70]. Therefore, specific modulation of the  
4 immune response is an attractive strategy to address these persistent, latent or immune-evading  
5 viruses, but also to develop novel and potentially broad-spectrum antiviral therapies. The current  
6 clinical practice already includes a form of immune modulation-based antiviral therapy: (pegylated)  
7 interferon used to be an important part of chronic viral hepatitis therapy, although it may have  
8 severe side effects.

9 Immune modulation as an antiviral therapy has distinct advantages, such as the possibility to target a  
10 wide array of viruses and other pathogens and a decreased risk for resistance development.  
11 However, there may be certain risks when modulating such a complex system, for instance the  
12 possibility to induce auto-immunity or cytokine storms, unwanted effects on commensal microbes or  
13 exacerbation of inflammatory diseases. This highlights the need for a very thorough understanding of  
14 the underlying immune mechanisms and extensive safety testing.

15 Modulation of innate immune signaling would be an interesting alternative for the direct use of  
16 interferon. One strategy employs the RIG-I agonist 5'pppRNA [71,72]: this double-stranded RNA  
17 oligomer activates several innate immune pathways and has broad-spectrum antiviral activity against  
18 multiple DNA and RNA viruses. In addition, it protects mice from lethal influenza virus infection [71].  
19 Nevertheless, 5'pppRNA still requires parenteral administration. The use of small molecules that  
20 trigger an interferon-response provides an interesting possibility to overcome parenteral  
21 administration, like for instance compound C3 [73].

22 An alternative and more specific approach is to selectively activate certain factors of the interferon  
23 effector system, thus obtaining a more targeted response and possibly avoiding interferon's side  
24 effects. One example are RNase L-activating molecules with a broad activity against RNA viruses [74].  
25 GSK983 is another small molecule that induces a specific subset of interferon-stimulated genes and  
26 has antiviral activity against a number of unrelated viruses, although not all pathogens are

1 susceptible [75]. Finally, two very attractive targets for the development of activating molecules may  
2 be the IFIT (interferon-induced protein with tetratricopeptide repeats) and IFITM (interferon-induced  
3 transmembrane protein) protein families which display broad-spectrum antiviral activity [76], but no  
4 such activating molecules have been described yet.

5 Another interesting development in antiviral immune modulation are double-stranded RNA (dsRNA)-  
6 activated caspase oligomerizers (DRACOs) [77]. These engineered proteins comprise a dsRNA-  
7 detection domain, an apoptosis-induction domain and a transduction tag for cellular delivery. Most  
8 viruses (including DNA viruses) produce long dsRNA during their replication cycle which is recognized  
9 by the dsRNA-detection domain. By fusing this detector to an apoptosis-inducing domain, DRACOs  
10 selectively eliminate virus-infected cells without harming non-infected cells. Consequently, these  
11 constructs have antiviral activity against a large spectrum of DNA and RNA viruses [77,78]. An *in vivo*  
12 proof-of-concept was provided in an influenza mouse model [77]. However, concerns regarding  
13 safety and specificity, delivery, cost and *in vivo* efficacy need to be addressed before DRACOs can  
14 advance into clinical trials.

15 Priorities for future research in antiviral immune modulation thus include (1) the discovery and  
16 development of more potent molecules with an extensive spectrum of susceptible viruses, (2) the *in*  
17 *vivo* validation of the available and novel molecules against clinically relevant pathogens and (3) the  
18 minimization of toxicity and side effects. A detailed understanding of the fundamental mechanisms  
19 governing the innate immune response is imperative in this regard.

## 20 **Conclusion and perspectives**

21 The past decades, antiviral research has resulted in over 30 marketed antiviral agents, most of them  
22 targeting a specific viral species. To cope with the threat of other viral pathogens, particularly  
23 (re-)emerging and neglected RNA viruses, the development of BSAA is critical. We discuss different  
24 approaches to obtain such molecules, i.e. focusing on nucleoside analogues, inhibitors of other  
25 conserved sites in viral enzymes, host-targeting antivirals and finally immune modulators. This list is

1 not exhaustive; other interesting strategies may emerge as our knowledge on viruses expands.  
2 Future research efforts should focus on validating these and other approaches and on the early  
3 development of candidate BSAA, but they should also be directed at increasing the fundamental  
4 understanding of the viral life cycle as this will provide important insights for the development of  
5 new broad-spectrum antiviral strategies.

## 6 **Key points**

- 7 • Broad-spectrum antiviral drugs are a prime strategy to cope with the large number of  
8 medically important, neglected and/or (re-)emerging viruses.
- 9 • Since some nucleoside analogues have proven to target a broad range of viruses, further  
10 research into these molecules may yield even more potent and broad-spectrum inhibitors.
- 11 • Another strategy to reach a broad spectrum of activity is to target relatively conserved viral  
12 enzymes, such as the viral protease.
- 13 • Host-targeting antiviral drugs are a third approach, probably with a high barrier to resistance.
- 14 • Finally, immune modulation uses specific properties of the host immune system and is one of  
15 the most promising strategies for future antiviral therapy.

1    **Acknowledgments**

2    None

3

4    **Financial support and sponsorship**

5    Yannick Debing and Leen Delang are funded by the Research Foundation Flanders (FWO), Belgium.

6

7    **Conflicts of interest**

8    None

## References

1. De Clercq E: **Antivirals: past, present and future.** *Biochem. Pharmacol.* 2013, **85**:727–744.
2. Paeshuyse J, Dallmeier K, Neyts J: **Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.** *Curr Opin Virol* 2011, **1**:590–598.
3. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, D’Alteroche L, et al.: **Ribavirin for chronic hepatitis E virus infection in transplant recipients.** *N. Engl. J. Med.* 2014, **370**:1111–1120.
4. Pelaez A, Lyon GM, Force SD, Ramirez AM, Neujahr DC, Foster M, Naik PM, Gal AA, Mitchell PO, Lawrence EC: **Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.** *J. Heart Lung Transplant.* 2009, **28**:67–71.
5. Bausch DG, Hadi CM, Khan SH, Lertora JLL: **Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.** *Clin. Infect. Dis.* 2010, **51**:1435–1441.
6. Moreli ML, Marques-Silva AC, Pimentel VA, da Costa VG: **Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: a meta-analysis.** *Virusdisease* 2014, **25**:385–389.
7. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al.: **Sofosbuvir for previously untreated chronic hepatitis C infection.** *N. Engl. J. Med.* 2013, **368**:1878–1887.
8. Dao Thi V, Debing Y, Wu X, Rice C, Neyts J, Moradpour D, Gouttenoire J: **Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin.** *Gastroenterology* 2015, **Submitted**.
9. Lee J-C, Tseng C-K, Wu Y-H, Kaushik-Basu N, Lin C-K, Chen W-C, Wu H-N: **Characterization of the activity of 2’-C-methylcytidine against dengue virus replication.** *Antiviral Res.* 2015, **116**:1–9.
10. Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MSJ, Neyts J: **The viral polymerase inhibitor 2’-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model.** *J. Virol.* 2013, **87**:11798–11805.
11. Goris N, De Palma A, Toussaint J-F, Musch I, Neyts J, De Clercq K: **2’-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus.** *Antiviral Res.* 2007, **73**:161–168.
12. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL: **Favipiravir (T-705), a novel viral RNA polymerase inhibitor.** *Antiviral Res.* 2013, **100**:446–54.
13. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren S a, Dong L, Retterer CJ, Eaton BP, Pegoraro G, et al.: **Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.** *Nature* 2014, **508**:402–405.

- 1 14. Poordad F, Lawitz E, Gitlin N, Rodriguez-Torres M, Box T, Nguyen T, Pietropaolo K, Liu W,  
2 Fiellman B, Mayers D: **Efficacy and safety of valopicitabine in combination with pegylated**  
3 **interferon-alpha (pegIFN) and ribavirin (RBV) in patients with chronic hepatitis C.**  
4 *Hepatology* 2007, **46**:866A.
- 5 15. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G: **Ribavirin-induced**  
6 **anemia: mechanisms, risk factors and related targets for future research.** *Curr. Med. Chem.*  
7 2006, **13**:3351–3357.
- 8 16. Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D, Thompson R: **Respiratory syncytial virus:**  
9 **current and emerging treatment options.** *Clinicoecon. Outcomes Res.* 2014, **6**:217–25.
- 10 17. Bruenn J: **A structural and primary sequence comparison of the viral RNA-dependent RNA**  
11 **polymerases.** *Nucleic Acids Res.* 2003, **31**:1821–1829.
- 12 18. Merino P: *Chemical Synthesis of Nucleoside Analogues.* Wiley; 2013.
- 13 19. Ferrari E, Huang H-C: **A novel hepatitis C virus NS5B polymerase assay of de novo initiated**  
14 **RNA synthesis directed from a heteropolymeric RNA template.** *Methods Mol. Biol.* 2013,  
15 **1030**:81–92.
- 16 20. Gong EY, Kenens H, Ivens T, Dockx K, Vermeiren K, Vandercruyssen G, Devogelaere B, Lory P,  
17 Kraus G: **Expression and purification of dengue virus NS5 polymerase and development of a**  
18 **high-throughput enzymatic assay for screening inhibitors of dengue polymerase.** *Methods*  
19 *Mol. Biol.* 2013, **1030**:237–47.
- 20 21. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA: *Virus Taxonomy: VIIIth Report of*  
21 *the International Committee on Taxonomy of Viruses.* 2005.
- 22 22. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich  
23 PS, Zhou R, Prins TJ, et al.: **In vitro antiviral activity of AG7088, a potent inhibitor of human**  
24 **rhinovirus 3C protease.** *Antimicrob. Agents Chemother.* 1999, **43**:2444–2450.
- 25 23. De Palma AM, De Palma AM, Pürstinger G, Pürstinger G, Wimmer E, Wimmer E, Patick AK,  
26 Patick AK, Andries K, Andries K, et al.: **Potential use of antiviral agents in polio eradication.**  
27 *Emerg. Infect. Dis.* 2008, **14**:545–551.
- 28 24. Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang K-O:  
29 **Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses,**  
30 **and Coronaviruses.** *J. Virol.* 2012, **86**:11754–11762.
- 31 25. Rocha-Pereira J, Nascimento MSJ, Ma Q, Hilgenfeld R, Neyts J, Jochmans D: **The enterovirus**  
32 **protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells**  
33 **from the norovirus replicon.** *Antimicrob. Agents Chemother.* 2014, **58**:4675–4681.
- 34 26. Kim Y, Shivanna V, Narayanan S, Prior AM, Weerasekara S, Hua DH, Galasiti Kankanamalage  
35 AC, Groutas WC, Chang K-O: **Broad-spectrum inhibitors against 3C-like proteases of feline**  
36 **coronaviruses and feline caliciviruses.** *J. Virol.* 2015, **89**:4942–4950.
- 37 27. Mazzon M, Mercer J: **Lipid Interactions During Virus Entry and Infection.** *Cell. Microbiol.*  
38 2014, **16**:1493–1502.

- 1 28. Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op De Beeck A,  
2 Neyts J: **Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C**  
3 **virus inhibitors and delay or prevent resistance development.** *Hepatology* 2009, **50**:6–16.
- 4 29. Ikeda M, Abe KI, Yamada M, Dansako H, Naka K, Kato N: **Different anti-HCV profiles of statins**  
5 **and their potential for combination therapy with interferon.** *Hepatology* 2006, **44**:117–125.
- 6 30. Del Real G, Jiménez-Baranda S, Mira E, Lacalle RA, Lucas P, Gómez-Moutón C, Alegret M, Peña  
7 JM, Rodríguez-Zapata M, Alvarez-Mon M, et al.: **Statins inhibit HIV-1 infection by down-**  
8 **regulating Rho activity.** *J. Exp. Med.* 2004, **2004**:541–547.
- 9 31. Giguère J, Tremblay MJ: **Statin Compounds Reduce Human Immunodeficiency Virus Type 1**  
10 **Replication by Preventing the Interaction between Virion-Associated Host Intercellular**  
11 **Adhesion Molecule 1 and Its Natural Cell Statin Compounds Reduce Human**  
12 **Immunodeficiency Virus Type 1 Replica.** *J. Virol.* 2004, **78**:1–5.
- 13 32. Liu S, Rodriguez A V., Tosteson MT: **Role of simvastatin and methyl- $\beta$ -cyclodextrin on**  
14 **inhibition of poliovirus infection.** *Biochem. Biophys. Res. Commun.* 2006, **347**:51–59.
- 15 33. Potena L, Frascaroli G, Grigioni F, Lazzarotto T, Magnani G, Tomasi L, Coccolo F, Gabrielli L,  
16 Magelli C, Landini MP, et al.: **Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition**  
17 **Limits Cytomegalovirus Infection in Human Endothelial Cells.** *Circulation* 2004, **109**:532–536.
- 18 34. Martínez-Gutierrez M, Castellanos JE, Gallego-Gómez JC: **Statins reduce dengue virus**  
19 **production via decreased virion assembly.** *Intervirology* 2011, **54**:202–216.
- 20 35. Gower TL, Graham BS: **Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In**  
21 **Vivo and In Vitro.** *Antimicrob. Agents Chemother.* 2001, **45**:1231–1237.
- 22 36. Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, Chen Y, Lv Y, Liu X, Liu Z: **Statin therapy improves**  
23 **response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and**  
24 **meta-analysis.** *Antiviral Res.* 2013, **98**:373–379.
- 25 37. Butt AA, Yan P, Bonilla H, Abou-Samra A-B, Shaikh OS, Simon TG, Chung RT, Rogal SS: **Effect of**  
26 **addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from**  
27 **ERCHIVES.** *Hepatology* 2015, doi:10.1002/hep.27835.
- 28 38. Blaising J, Polyak SJ, Pécheur EI: **Arbidol as a broad-spectrum antiviral: An update.** *Antiviral*  
29 *Res.* 2014, **107**:84–94.
- 30 39. Teissier E, Zandomenighi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL,  
31 Böckmann A, Meier BH, Penin F, et al.: **Mechanism of inhibition of enveloped virus**  
32 **membrane fusion by the antiviral drug arbidol.** *PLoS One* 2011, **6**:e15874.
- 33 40. Liu MY, Wang S, Yao WF, Wu H zhe, Meng SN, Wei MJ: **Pharmacokinetic properties and**  
34 **bioequivalence of two formulations of arbidol: An open-label, single-dose, randomized-**  
35 **sequence, two-period crossover study in healthy chinese male volunteers.** *Clin. Ther.* 2009,  
36 **31**:784–792.



- 1 41. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ,  
2 Aguilar HC, et al.: **A broad-spectrum antiviral targeting entry of enveloped viruses.** *Proc.*  
3 *Natl. Acad. Sci. U. S. A.* 2010, **107**:3157–3162.
- 4 42. Vigant F, Lee J, Hollmann A, Tanner LB, Akyol Ataman Z, Yun T, Shui G, Aguilar HC, Zhang D,  
5 Meriwether D, et al.: **A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target**  
6 **Virus-Cell Fusion.** *PLoS Pathog.* 2013, **9**:e1003297.
- 7 43. Vigant F, Santos NC, Lee B: **Broad-spectrum antivirals against viral fusion.** *Nat. Rev.*  
8 *Microbiol.* 2015, **13**:426–437.
- 9 44. Song J-M, Seong B-L: **Viral membranes: an emerging antiviral target for enveloped viruses?**  
10 *Expert Rev. Anti. Infect. Ther.* 2010, **8**:635–638.
- 11 45. Zasloff M, Adams AP, Beckerman B, Campbell A, Han Z, Luijten E, Meza I, Julander J, Mishra A,  
12 Qu W, et al.: **Squalamine as a broad-spectrum systemic antiviral agent with therapeutic**  
13 **potential.** *Proc. Natl. Acad. Sci.* 2011, **108**:15978–15983.
- 14 46. Sumioka A, Yan D, Tomita S: **TARP Phosphorylation Regulates Synaptic AMPA Receptors**  
15 **through Lipid Bilayers.** *Neuron* 2010, **66**:755–767.
- 16 47. Zhang X, Rao MN, Jones SR, Shao B, Feibush P, McGuigan M, Tzodikov N, Feibush B,  
17 Sharkansky I, Snyder B, et al.: **Synthesis of squalamine utilizing a readily accessible**  
18 **spermidine equivalent.** *J. Org. Chem.* 1998, **63**:8599–8603.
- 19 48. Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ,  
20 Hawkins MJ: **A Phase I and Pharmacokinetic Study of Squalamine , a Novel Antiangiogenic**  
21 **Agent , in Patients with Advanced Cancers A Phase I and Pharmacokinetic Study of**  
22 **Squalamine , a Novel Antiangiogenic Agent , in Patients with Advanced Cancers 1.** *Clin.*  
23 *Cancer Res.* 2001, **7**:3912–3919.
- 24 49. Rossignol JF, Ayoub A, Ayers MS: **Treatment of diarrhea caused by Cryptosporidium parvum:**  
25 **a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide.** *J. Infect.*  
26 *Dis.* 2001, **184**:103–106.
- 27 50. Rossignol J-F: **Nitazoxanide: A first-in-class broad-spectrum antiviral agent.** *Antiviral Res.*  
28 2014, **110**:94–103.
- 29 51. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG: **Thiazolides, a new class of anti-**  
30 **influenza molecules targeting viral hemagglutinin at the post-translational level.** *J. Biol.*  
31 *Chem.* 2009, **284**:29798–29808.
- 32 52. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS: **The Anti-**  
33 **Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2 $\alpha$**   
34 **Via Protein Kinase Activated by Double-Stranded RNA Activation.** *Gastroenterology* 2009,  
35 **137**:1827–1835.
- 36 53. Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol  
37 JF: **Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A**  
38 **double-blind, randomised, placebo-controlled, phase 2b/3 trial.** *Lancet Infect. Dis.* 2014,  
39 **14**:609–618.

- 1 54. Rossignol J-F, El-Gohary YM: **Nitazoxanide in the treatment of viral gastroenteritis: a**  
2 **randomized double-blind placebo-controlled clinical trial.** *Aliment. Pharmacol. Ther.* 2006,  
3 **24**:1423–1430.
- 4 55. Rossignol J-F, Elfert A, El-Gohary Y, Keeffe EB: **Improved virologic response in chronic**  
5 **hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.**  
6 *Gastroenterology* 2009, **136**:856–862.
- 7 56. Göthel SF, Marahiel MA: **Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous**  
8 **folding catalysts.** *Cell. Mol. Life Sci.* 1999, **55**:423–436.
- 9 57. Frausto SD, Lee E, Tang H: **Cyclophilins as modulators of viral replication.** *Viruses* 2013,  
10 **5**:1684–1701.
- 11 58. Davis TL, Walker JR, Campagna-Slater V, Finerty PJ, Finerty PJ, Paramanathan R, Bernstein G,  
12 Mackenzie F, Tempel W, Ouyang H, et al.: **Structural and biochemical characterization of the**  
13 **human cyclophilin family of peptidyl-prolyl isomerases.** *PLoS Biol.* 2010, **8**:e1000439.
- 14 59. Hopkins S, Dimassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scoreaux B, Mosier S,  
15 Kowalczyk P, Ribeill Y, et al.: **The cyclophilin inhibitor SCY-635 suppresses viral replication**  
16 **and induces endogenous interferons in patients with chronic HCV genotype 1 infection.** *J.*  
17 *Hepatol.* 2012, **57**:47–54.
- 18 60. Flisiak R, Feinman S V., Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE,  
19 Mazzella G, Vandelli C, Nicolas-Métral V, et al.: **The cyclophilin inhibitor debio 025 combined**  
20 **with PEG IFN $\alpha$ 2a significantly reduces viral load in treatment-naïve hepatitis C patients.**  
21 *Hepatology* 2009, **49**:1460–1468.
- 22 61. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Lopez MZ, Lohmann V, Luban J,  
23 Bartenschlager R: **Essential role of cyclophilin A for hepatitis C virus replication and virus**  
24 **production and possible link to polyprotein cleavage kinetics.** *PLoS Pathog.* 2009,  
25 **5**:e1000546.
- 26 62. Coelmont L, Hanouille X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I,  
27 Paeshuyse J, Vuagniaux G, et al.: **Deb025 (Alisporivir) inhibits hepatitis c virus replication by**  
28 **preventing a cyclophilin a induced Cis-trans isomerisation in domain ii of NS5A.** *PLoS One*  
29 2010, **5**:e13687.
- 30 63. Delang L, Vliegen I, Froeyen M, Neyts J: **Comparative study of the genetic barriers and**  
31 **pathways towards resistance of selective inhibitors of hepatitis C virus replication.**  
32 *Antimicrob. Agents Chemother.* 2011, **55**:4103–4113.
- 33 64. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP: **Crystal**  
34 **structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.** *Cell*  
35 1996, **87**:1285–1294.
- 36 65. Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch L, Ward P, Jones MJ, Stoddart C,  
37 Scalfaro P, Dumont JM, et al.: **Naturally occurring capsid substitutions render HIV-1**  
38 **cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey**  
39 **cells.** *J. Biol. Chem.* 2005, **280**:40293–40300.

66. Gallay P a., Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B: **Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.** *Viruses* 2013, **5**:981–997.
67. Colgan J, Asmal M, Neagu M, Yu B, Schneidkraut J, Lee Y, Sokolskaja E, Andreotti A, Luban J: **Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk.** *Immunity* 2004, **21**:189–201.
68. Braaten D, Luban J: **Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells.** *EMBO J.* 2001, **20**:1300–1309.
69. Openshaw PJM, Tregoning JS: **Immune responses and disease enhancement during respiratory syncytial virus infection.** *Clin. Microbiol. Rev.* 2005, **18**:541–555.
70. Nagy P, Pogany J: **The dependence of viral RNA replication on co-opted host factors.** *Nat. Rev. Microbiol.* 2012, **10**:137–149.
71. Goulet M-L, OLAGNIE D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, Janelle V, Arguello M, Paquet M, Ghneim K, et al.: **Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity.** *PLoS Pathog.* 2013, **9**:e1003298.
72. OLAGNIE D, Scholte FEM, Chiang C, Albulescu IC, Nichols C, He Z, Lin R, Snijder EJ, van Hemert MJ, Hiscott J: **Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.** *J. Virol.* 2014, **88**:4180–4194.
73. Martínez-Gil L, Ayllon J, Ortigoza MB, García-Sastre A, Shaw ML, Palese P: **Identification of small molecules with type I interferon inducing properties by high-throughput screening.** *PLoS One* 2012, **7**:e49049.
74. Thakur CS, Jha BK, Dong B, Das Gupta J, Silverman KM, Mao H, Sawai H, Nakamura AO, Banerjee AK, Gudkov A, et al.: **Small-molecule activators of RNase L with broad-spectrum antiviral activity.** *Proc. Natl. Acad. Sci. U. S. A.* 2007, **104**:9585–9590.
75. Harvey R, Brown K, Zhang Q, Gartland M, Walton L, Talarico C, Lawrence W, Selleseth D, Coffield N, Leary J, et al.: **GSK983: a novel compound with broad-spectrum antiviral activity.** *Antiviral Res.* 2009, **82**:1–11.
76. Diamond MS, Farzan M: **The broad-spectrum antiviral functions of IFIT and IFITM proteins.** *Nat. Rev. Immunol.* 2013, **13**:46–57.
77. Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD: **Broad-spectrum antiviral therapeutics.** *PLoS One* 2011, **6**:e22572.
78. Guo C, Chen L, Mo D, Chen Y, Liu X: **DRACO inhibits porcine reproductive and respiratory syndrome virus replication in vitro.** *Arch. Virol.* 2015, **160**:1239–1247.

1   **Highlights:**

2   13. Warren et al 2014: \* Recent study describing a new broad-spectrum antiviral nucleoside  
3       analogue including in vivo testing against filoviruses.

4   43. Vigant et al 2015: \*\* A comprehensive review of the broad-spectrum potential of antivirals that  
5       target the membrane fusion process.

6   50. Rossignol 2014: \* A complete account on the current knowledge on nitazoxanide, a repurposed  
7       broad-spectrum antiviral drug

8   72. Olganier et al 2014: \* An interesting study describing inhibition of arthropod-borne virus  
9       replication by the RIG-I agonist 5'pppRNA